<DOC>
	<DOC>NCT02284854</DOC>
	<brief_summary>Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ pharmacokinetics.</brief_summary>
	<brief_title>Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine</brief_title>
	<detailed_description>Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ pharmacokinetics. Each patient participated in the study for approximately 9 weeks. The clinical portion of the study was completed in approximately 3 months. Subjects received the treatments during 35 days.</detailed_description>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male and female subjects aged 18 to 45 years inclusive; Body mass index (BMI) between 18 and 30 kg/m2 inclusive; Healthy as determined by prestudy medical history, physical examination, vital signs, and 12lead electrocardiogram (ECG); negative tests for Hepatitis B surface Antigen (HBsAg), antiHCVAb and Human Immunodeficiency Virus (HIV)1 and HIV2 Ab at screening; Clinical laboratory test results clinically acceptable at screening and admission to each treatment period; Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period; Nonsmokers or exsmokers; Able and willing to give written informed consent; If female, not of childbearing potential by reason of surgery or, if of childbearing potential, she used a doublebarrier method of contraception: 1 male barrier method [male condom] plus 1 female barrier method (diaphragm, spermicide, or intrauterine device); If female, had a negative urine pregnancy test at screening and admission to each treatment period. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders; have a clinically relevant surgical history; History of relevant atopy or any drug hypersensitivity (including known hypersensitivity to ESL or other carboxamide derivatives [e.g., carbamazepine, oxcarbazepine] or any of its excipients; known hypersensitivity to drugs structurally related to carbamazepine [e.g.: tricyclic antidepressants] or any of its excipients); Second or thirddegree atrioventricular blockade not corrected with a pacemaker or any other clinically significant abnormality in the 12lead ECG as determined by the investigator; History of alcoholism or drug abuse; Consumed more than 14 units1 of alcohol a week; Significant infection or known inflammatory process on screening or admission to each treatment period; Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period; Use of medicines within two weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion; Had donated or received any blood or blood products within the 3 months prior to screening; Vegetarians, vegans or have other medical dietary restrictions; Could not communicate reliably with the investigator; was unlikely to cooperate with the requirements of the study; Unwilling or unable to give written informed consent; If female, was pregnant or breastfeeding; If female, was of childbearing potential and did not use an accepted effective contraceptive method or used hormonal contraceptives; Had received an investigational drug within 3 months of screening or was currently participating in another study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>